nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—CYP1A2—Methimazole—Graves' disease	0.355	0.426	CbGbCtD
Vemurafenib—CYP2D6—Methimazole—Graves' disease	0.292	0.351	CbGbCtD
Vemurafenib—CYP3A4—Methimazole—Graves' disease	0.186	0.223	CbGbCtD
Vemurafenib—Erythema nodosum—Propylthiouracil—Graves' disease	0.0239	0.195	CcSEcCtD
Vemurafenib—Vasculitis—Propylthiouracil—Graves' disease	0.0106	0.0866	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Methimazole—Graves' disease	0.00667	0.0545	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Propylthiouracil—Graves' disease	0.00567	0.0463	CcSEcCtD
Vemurafenib—Alopecia—Methimazole—Graves' disease	0.0054	0.0441	CcSEcCtD
Vemurafenib—BRAF—pituitary gland—Graves' disease	0.00466	0.118	CbGeAlD
Vemurafenib—BRAF—adipose tissue—Graves' disease	0.00464	0.117	CbGeAlD
Vemurafenib—Alopecia—Propylthiouracil—Graves' disease	0.00459	0.0375	CcSEcCtD
Vemurafenib—Myalgia—Methimazole—Graves' disease	0.00453	0.037	CcSEcCtD
Vemurafenib—Arthralgia—Methimazole—Graves' disease	0.00453	0.037	CcSEcCtD
Vemurafenib—Dysgeusia—Propylthiouracil—Graves' disease	0.00443	0.0362	CcSEcCtD
Vemurafenib—RAF1—eye—Graves' disease	0.00418	0.106	CbGeAlD
Vemurafenib—RAF1—connective tissue—Graves' disease	0.00403	0.102	CbGeAlD
Vemurafenib—BRAF—thyroid gland—Graves' disease	0.00401	0.102	CbGeAlD
Vemurafenib—Musculoskeletal discomfort—Methimazole—Graves' disease	0.00396	0.0323	CcSEcCtD
Vemurafenib—Myalgia—Propylthiouracil—Graves' disease	0.00385	0.0315	CcSEcCtD
Vemurafenib—Arthralgia—Propylthiouracil—Graves' disease	0.00385	0.0315	CcSEcCtD
Vemurafenib—Body temperature increased—Methimazole—Graves' disease	0.00343	0.028	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Propylthiouracil—Graves' disease	0.00336	0.0275	CcSEcCtD
Vemurafenib—RAF1—pituitary gland—Graves' disease	0.0031	0.0785	CbGeAlD
Vemurafenib—RAF1—adipose tissue—Graves' disease	0.00309	0.0781	CbGeAlD
Vemurafenib—Pruritus—Methimazole—Graves' disease	0.00307	0.0251	CcSEcCtD
Vemurafenib—Body temperature increased—Propylthiouracil—Graves' disease	0.00292	0.0238	CcSEcCtD
Vemurafenib—Vomiting—Methimazole—Graves' disease	0.00276	0.0225	CcSEcCtD
Vemurafenib—Rash—Methimazole—Graves' disease	0.00274	0.0224	CcSEcCtD
Vemurafenib—Dermatitis—Methimazole—Graves' disease	0.00274	0.0223	CcSEcCtD
Vemurafenib—Headache—Methimazole—Graves' disease	0.00272	0.0222	CcSEcCtD
Vemurafenib—RAF1—thyroid gland—Graves' disease	0.00267	0.0676	CbGeAlD
Vemurafenib—Pruritus—Propylthiouracil—Graves' disease	0.00261	0.0213	CcSEcCtD
Vemurafenib—Nausea—Methimazole—Graves' disease	0.00258	0.0211	CcSEcCtD
Vemurafenib—Vomiting—Propylthiouracil—Graves' disease	0.00235	0.0192	CcSEcCtD
Vemurafenib—Rash—Propylthiouracil—Graves' disease	0.00233	0.019	CcSEcCtD
Vemurafenib—Dermatitis—Propylthiouracil—Graves' disease	0.00233	0.019	CcSEcCtD
Vemurafenib—Headache—Propylthiouracil—Graves' disease	0.00231	0.0189	CcSEcCtD
Vemurafenib—Nausea—Propylthiouracil—Graves' disease	0.00219	0.0179	CcSEcCtD
Vemurafenib—ABCC1—pituitary gland—Graves' disease	0.00155	0.0392	CbGeAlD
Vemurafenib—ABCC1—adipose tissue—Graves' disease	0.00154	0.039	CbGeAlD
Vemurafenib—ABCC1—thyroid gland—Graves' disease	0.00134	0.0338	CbGeAlD
Vemurafenib—ABCG2—pituitary gland—Graves' disease	0.00128	0.0325	CbGeAlD
Vemurafenib—ABCG2—adipose tissue—Graves' disease	0.00128	0.0323	CbGeAlD
Vemurafenib—ABCG2—thyroid gland—Graves' disease	0.00111	0.028	CbGeAlD
Vemurafenib—CYP1A2—thyroid gland—Graves' disease	0.00106	0.0269	CbGeAlD
Vemurafenib—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SCGB3A2—Graves' disease	0.000265	0.0549	CbGpPWpGaD
Vemurafenib—BRAF—TSH signaling pathway—TSHR—Graves' disease	0.00018	0.0373	CbGpPWpGaD
Vemurafenib—BRAF—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.000146	0.0302	CbGpPWpGaD
Vemurafenib—RAF1—CXCR3-mediated signaling events—CXCL10—Graves' disease	0.000125	0.0259	CbGpPWpGaD
Vemurafenib—RAF1—TSH signaling pathway—TSHR—Graves' disease	0.000125	0.0258	CbGpPWpGaD
Vemurafenib—BRAF—Transmission across Chemical Synapses—GABRA3—Graves' disease	0.00011	0.0227	CbGpPWpGaD
Vemurafenib—RAF1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GABRA3—Graves' disease	0.000101	0.0209	CbGpPWpGaD
Vemurafenib—BRAF—Downstream signaling in naïve CD8+ T cells—CD8A—Graves' disease	9.87e-05	0.0204	CbGpPWpGaD
Vemurafenib—BRAF—Downstream signaling in naïve CD8+ T cells—FASLG—Graves' disease	9.28e-05	0.0192	CbGpPWpGaD
Vemurafenib—RAF1—Ion channel transport—GABRA3—Graves' disease	9e-05	0.0186	CbGpPWpGaD
Vemurafenib—BRAF—Downstream signaling in naïve CD8+ T cells—IL2RA—Graves' disease	8.9e-05	0.0184	CbGpPWpGaD
Vemurafenib—RAF1—IL-2 Signaling Pathway—IL2RA—Graves' disease	8.84e-05	0.0183	CbGpPWpGaD
Vemurafenib—BRAF—Downstream signaling in naïve CD8+ T cells—HLA-A—Graves' disease	8.8e-05	0.0182	CbGpPWpGaD
Vemurafenib—BRAF—Neuronal System—GABRA3—Graves' disease	8.42e-05	0.0174	CbGpPWpGaD
Vemurafenib—RAF1—Interleukin-2 signaling—IL2RA—Graves' disease	8.08e-05	0.0167	CbGpPWpGaD
Vemurafenib—RAF1—Transmission across Chemical Synapses—GABRA3—Graves' disease	7.6e-05	0.0157	CbGpPWpGaD
Vemurafenib—RAF1—Interleukin-11 Signaling Pathway—ICAM1—Graves' disease	7.38e-05	0.0153	CbGpPWpGaD
Vemurafenib—RAF1—IL2-mediated signaling events—IL2RA—Graves' disease	7.23e-05	0.0149	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—CD8A—Graves' disease	6.83e-05	0.0141	CbGpPWpGaD
Vemurafenib—RAF1—SHP2 signaling—IL2RA—Graves' disease	6.83e-05	0.0141	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—FASLG—Graves' disease	6.42e-05	0.0133	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—IL2RA—Graves' disease	6.16e-05	0.0127	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—HLA-A—Graves' disease	6.09e-05	0.0126	CbGpPWpGaD
Vemurafenib—BRAF—Downstream signaling in naïve CD8+ T cells—IFNG—Graves' disease	5.87e-05	0.0121	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—GABRA3—Graves' disease	5.82e-05	0.012	CbGpPWpGaD
Vemurafenib—RAF1—TCR Signaling Pathway—CD8A—Graves' disease	5.33e-05	0.011	CbGpPWpGaD
Vemurafenib—RAF1—TCR Signaling Pathway—FAS—Graves' disease	4.83e-05	0.00999	CbGpPWpGaD
Vemurafenib—RAF1—IL2-mediated signaling events—IFNG—Graves' disease	4.77e-05	0.00986	CbGpPWpGaD
Vemurafenib—RAF1—SHP2 signaling—IFNG—Graves' disease	4.5e-05	0.00931	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—HLA-E—Graves' disease	4.45e-05	0.0092	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—FASLG—Graves' disease	4.4e-05	0.00909	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—FAS—Graves' disease	4.24e-05	0.00876	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—HLA-E—Graves' disease	4.19e-05	0.00866	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Interleukins—IL2RA—Graves' disease	4.15e-05	0.00858	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—IFNG—Graves' disease	4.06e-05	0.0084	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—IFNG—Graves' disease	4.05e-05	0.00837	CbGpPWpGaD
Vemurafenib—BRAF—Downstream signaling in naïve CD8+ T cells—TNF—Graves' disease	3.8e-05	0.00786	CbGpPWpGaD
Vemurafenib—RAF1—TWEAK Signaling Pathway—TNF—Graves' disease	3.77e-05	0.0078	CbGpPWpGaD
Vemurafenib—BRAF—Senescence and Autophagy in Cancer—IL1B—Graves' disease	3.61e-05	0.00747	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—ICAM1—Graves' disease	3.53e-05	0.0073	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—GC—Graves' disease	3.51e-05	0.00726	CbGpPWpGaD
Vemurafenib—RAF1—Aryl Hydrocarbon Receptor—TNF—Graves' disease	3.51e-05	0.00726	CbGpPWpGaD
Vemurafenib—RAF1—Ceramide signaling pathway—TNF—Graves' disease	3.39e-05	0.00701	CbGpPWpGaD
Vemurafenib—RAF1—Leptin signaling pathway—IL1B—Graves' disease	3.27e-05	0.00676	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—GABRA3—Graves' disease	3.13e-05	0.00647	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—GABRA3—Graves' disease	3.1e-05	0.00642	CbGpPWpGaD
Vemurafenib—RAF1—TCR Signaling Pathway—CD4—Graves' disease	3.06e-05	0.00633	CbGpPWpGaD
Vemurafenib—RAF1—Cardiac Hypertrophic Response—TNF—Graves' disease	3.04e-05	0.00629	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—FASLG—Graves' disease	3.04e-05	0.00629	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—HLA-B—Graves' disease	2.98e-05	0.00617	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—FAS—Graves' disease	2.93e-05	0.00606	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HLA-E—Graves' disease	2.9e-05	0.006	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—ICAM1—Graves' disease	2.87e-05	0.00594	CbGpPWpGaD
Vemurafenib—RAF1—TCR Signaling Pathway—IL1B—Graves' disease	2.83e-05	0.00584	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—IFNG—Graves' disease	2.8e-05	0.00579	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—FASLG—Graves' disease	2.74e-05	0.00567	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—GABRA3—Graves' disease	2.73e-05	0.00565	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—IFNG—Graves' disease	2.69e-05	0.00556	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—FAS—Graves' disease	2.65e-05	0.00547	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling in naïve CD8+ T cells—TNF—Graves' disease	2.63e-05	0.00544	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—IL1B—Graves' disease	2.5e-05	0.00517	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—IL1B—Graves' disease	2.48e-05	0.00513	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Interleukins—IL1B—Graves' disease	2.44e-05	0.00505	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—IL1B—Graves' disease	2.4e-05	0.00496	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	2.34e-05	0.00484	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HLA-DQB1—Graves' disease	2.3e-05	0.00476	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—ICAM1—Graves' disease	2.28e-05	0.00472	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—IFNG—Graves' disease	2.19e-05	0.00452	CbGpPWpGaD
Vemurafenib—RAF1—MicroRNAs in cardiomyocyte hypertrophy—TNF—Graves' disease	2.17e-05	0.00448	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IFIH1—Graves' disease	2.07e-05	0.00428	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HLA-B—Graves' disease	2.07e-05	0.00427	CbGpPWpGaD
Vemurafenib—BRAF—Disease—B3GNT2—Graves' disease	2.06e-05	0.00427	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—Graves' disease	2.04e-05	0.00422	CbGpPWpGaD
Vemurafenib—RAF1—TNF alpha Signaling Pathway—TNF—Graves' disease	2.02e-05	0.00417	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—IL1B—Graves' disease	1.95e-05	0.00403	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL2RA—Graves' disease	1.94e-05	0.00401	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HLA-A—Graves' disease	1.92e-05	0.00396	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—GC—Graves' disease	1.91e-05	0.00394	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—Graves' disease	1.82e-05	0.00376	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—TNF—Graves' disease	1.8e-05	0.00372	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HLA-DRB1—Graves' disease	1.75e-05	0.00362	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—TNF—Graves' disease	1.74e-05	0.0036	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IFNG—Graves' disease	1.74e-05	0.00359	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—IL1B—Graves' disease	1.72e-05	0.00355	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—GABRA3—Graves' disease	1.69e-05	0.00348	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—ICAM1—Graves' disease	1.68e-05	0.00347	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HLA-E—Graves' disease	1.63e-05	0.00336	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—GC—Graves' disease	1.56e-05	0.00323	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-E—Graves' disease	1.56e-05	0.00323	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL1B—Graves' disease	1.55e-05	0.0032	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD40—Graves' disease	1.53e-05	0.00316	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CTLA4—Graves' disease	1.51e-05	0.00311	CbGpPWpGaD
Vemurafenib—RAF1—Disease—B3GNT2—Graves' disease	1.43e-05	0.00295	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—B3GNT2—Graves' disease	1.42e-05	0.00293	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TNF—Graves' disease	1.41e-05	0.00293	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—TSHR—Graves' disease	1.4e-05	0.0029	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—GC—Graves' disease	1.38e-05	0.00285	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—GC—Graves' disease	1.33e-05	0.00276	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—Graves' disease	1.32e-05	0.00273	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—Graves' disease	1.32e-05	0.00273	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IFNG—Graves' disease	1.28e-05	0.00264	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—IL2RA—Graves' disease	1.26e-05	0.00261	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TNF—Graves' disease	1.24e-05	0.00257	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-DQB1—Graves' disease	1.24e-05	0.00256	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—IL2RA—Graves' disease	1.21e-05	0.0025	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFIH1—Graves' disease	1.2e-05	0.00249	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TSHR—Graves' disease	1.2e-05	0.00248	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—B3GNT2—Graves' disease	1.19e-05	0.00245	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HLA-B—Graves' disease	1.16e-05	0.0024	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD8A—Graves' disease	1.16e-05	0.00239	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL1B—Graves' disease	1.14e-05	0.00236	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—TNF—Graves' disease	1.12e-05	0.00232	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—Graves' disease	1.12e-05	0.00232	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-B—Graves' disease	1.11e-05	0.0023	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—B3GNT2—Graves' disease	1.04e-05	0.00216	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-A—Graves' disease	1.03e-05	0.00213	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-E—Graves' disease	9.48e-06	0.00196	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-DRB1—Graves' disease	9.42e-06	0.00195	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD40—Graves' disease	9.26e-06	0.00192	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CTLA4—Graves' disease	9.13e-06	0.00189	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL10—Graves' disease	9.06e-06	0.00187	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—ICAM1—Graves' disease	9.05e-06	0.00187	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GC—Graves' disease	8.49e-06	0.00176	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HLA-A—Graves' disease	8.35e-06	0.00173	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TSHR—Graves' disease	8.28e-06	0.00171	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL10—Graves' disease	7.74e-06	0.0016	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DQB1—Graves' disease	7.52e-06	0.00155	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD8A—Graves' disease	7.02e-06	0.00145	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GC—Graves' disease	7.01e-06	0.00145	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2RA—Graves' disease	6.93e-06	0.00143	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CD4—Graves' disease	6.92e-06	0.00143	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-B—Graves' disease	6.75e-06	0.0014	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD4—Graves' disease	6.65e-06	0.00137	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2RA—Graves' disease	6.5e-06	0.00134	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—B3GNT2—Graves' disease	6.44e-06	0.00133	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2RA—Graves' disease	6.33e-06	0.00131	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-A—Graves' disease	6.26e-06	0.00129	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GC—Graves' disease	5.94e-06	0.00123	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2RA—Graves' disease	5.91e-06	0.00122	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HLA-A—Graves' disease	5.78e-06	0.00119	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HLA-A—Graves' disease	5.73e-06	0.00118	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DRB1—Graves' disease	5.72e-06	0.00118	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ICAM1—Graves' disease	5.49e-06	0.00113	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD4—Graves' disease	5.38e-06	0.00111	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL10—Graves' disease	5.35e-06	0.00111	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—B3GNT2—Graves' disease	5.31e-06	0.0011	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—Graves' disease	5.25e-06	0.00109	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GC—Graves' disease	4.58e-06	0.000948	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—B3GNT2—Graves' disease	4.5e-06	0.000931	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNG—Graves' disease	4.17e-06	0.000863	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2RA—Graves' disease	4.09e-06	0.000846	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD4—Graves' disease	4.03e-06	0.000834	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—Graves' disease	3.72e-06	0.00077	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD4—Graves' disease	3.72e-06	0.00077	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD4—Graves' disease	3.69e-06	0.000763	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—B3GNT2—Graves' disease	3.47e-06	0.000718	CbGpPWpGaD
